Amarin To Present New Analyses Affirming Robustness of Data from REDUCE-IT and Additional Mechanisms of Action of Eicosapentaenoic Acid (EPA) at American Heart Association (AHA) Scientific Sessions 2025 - Amarin Corp (NASDAQ:AMRN)

Amarin (AMRN) reported Q2 2026 results on an earnings call. Total net revenue was $42.2M, down 42% year over year, mainly due to a $25M upfront licensing payment in 2025. U.S. product revenue fell to $32.2M, while Europe product revenue rose to $5.4M. Operating loss narrowed to $12.0M and cash and investments were $314.6M.

Strong international demand growth and lower operating expenses supported improved profitability metrics as Amarin reaffirmed confidence in its global commercialization strategy. Key Investor Takeaways Amarin (NASDAQ:AMRN) reported strong international in-market demand growth, with partner network sales increasing 59% year over year despite lower reported revenue.

AMARIN CORP PLC\UK (AMRN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Amarin Reports 2026 Second Quarter Financial Results Demonstrating Early Success of Fully Partnered International Commercial Strategy and Continued Leading U.S. Market Presence Q2 2026 Results Highlight Global Volume Growth, Lower Operating Expenses and Positive Cash

Amarin (NASDAQ: AMRN) reported Q2 2026 results for the quarter ended June 30, 2026. Total net revenue fell to $42.2 million from $72.7 million in Q2 2025, while operating expenses dropped 59% to $27.0 million. The company said in-market demand for VASCEPA/VAZKEPA rose 59% YoY across its partner network and U.S. IPE market share increased to 48%. It expects FY 2026 cash growth and continued international volume growth under its Recordati partnership.

BioNTech (NASDAQ:BNTX) halted a mid-stage trial of its mRNA cancer vaccine, autogene cevumeran, due to an overall survival imbalance. The decision raises concerns about its mRNA strategy in colorectal cancer and other 'cold' tumors. BioNTech plans to continue other trials, including one for pancreatic cancer and BNT113 for head and neck cancer. The company also focuses on diversifying its oncology pipeline. According to Reuters, the news caused a 7.5% drop in BioNTech's US-listed shares.

Volkswagen (VW) plans to produce components for Israel's Iron Dome missile defense system at its Osnabrück, Germany factory. The move is part of VW's restructuring efforts amid economic challenges and competition. The project involves a joint venture with Israeli defense company Rafael and the German state of Lower Saxony, aiming to overcome opposition from Qatar's sovereign wealth fund, a VW stakeholder. This marks VW's return to defense-related manufacturing as European defense spending rises.